| Vol. 11.07 – 24 February, 2022 |
| |
|
|
| Scientists indicated that targeting IL6/JAK2/STAT3 signaling in activated microglia may be a promising new approach for inhibiting brain metastasis in NSCLC patients. [Signal Transduction and Targeted Therapy] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Exposure of lung epithelial and endothelial cells to nitrogen mustard led to intracellular oxidative stress that compromised the intrinsic cell membrane repair function of MG53. [Journal of Cellular and Molecular Medicine] |
|
|
|
| Researchers demonstrated that fibroblast programmed death ligand-1 (PD-L1) may have promoted pulmonary fibrosis through both Smad3 and β-catenin signaling and may represent a novel interventional target for idiopathic pulmonary fibrosis. [Scientific Reports] |
| |
|
|
| Scientists investigated the function of the oncogenic BAP1/ASXL3/BRD4 epigenetic axis in small cell lung cancer by developing a next-generation BAP1 inhibitor. [Oncogene] |
|
|
|
| Researchers used a humanized mouse model to show that while carboplatin plus pembrolizumab reduced tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2, delivered systemically in nanovesicles, to this combination, eradicated tumors in the majority of animals. [Communications Biology] |
|
|
|
| The authors showed that clinically, plasma interleukin-6 (IL-6) level predicted osimertinib efficacy in epidermal growth factor receptor mutant NSCLC patients. [Communications Biology] |
|
|
|
| Investigators discovered a mechanical correlation between leucine proline-enriched proteoglycan 1 (LEPRE1) and pelitinib drug sensitivity using in silico statistical methods and confirmed the correlation in acute myeloid leukemia and A549 lung cancer cells. [Scientific Reports] |
|
|
|
| Quercitrin prohibited the cell viability and clone-formation of lung adenocarcinoma (LUAD) cells in vitro. Quercitrin treatment reduced the aggressive phenotypes in LUAD cells. [Bioengineered] |
|
|
|
| Investigators suggested that circ-UBE2D2 promoted the proliferation, migration and invasion but restrained apoptosis of lung cancer cells by regulating miR-376a-3p/eukaryotic translation initiation factor 4γ2 axis. [Bioengineered] |
| |
|
|
|
| Scientists review current clinical trials of epigenetic therapy against small cell lung cancer and the mechanisms of epigenetic inhibitors to boost antitumor immunity. [Seminars in Cancer Biology] |
|
|
|
| The authors summarize the biological characteristics and functions of extracellular vesicles ncRNAs in the biological processes of lung cancer (LC), focusing on their potential to serve as diagnostic and prognostic biomarkers of LC as well as their probable role in the clinical treatment of LC. [Molecular Therapy Oncolytics] |
|
|
|
|
| Mauna Kea Technologies announced that, as part of its collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson, initial enrollment of patients has begun in a prospective, multi-center, open-label, single-arm clinical feasibility study sponsored by LCI. [Mauna Kea Technologies] |
|
|
|
| Merck KGaA, announced that the European Commission has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping. [Merck KGaA] |
|
|
|
|
| April 7 – April 9 Rome, Italy & Virtual |
|
|
|
|
|
| BC Cancer Research Institute – Vancouver, British Columbia, Canada |
|
|
|
| University of California San Francisco – San Francisco, California, United States |
|
|
|
| Babraham Institute – Babraham, Cambridgeshire, United Kingdom |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
| Wayne State University School of Medicine – Detroit, Michigan, United States |
|
|
|
|